Advertisement

Prevention of Infection

  • Brian T. FisherEmail author
  • Christopher C. Dvorak
  • Sarah Alexander
Chapter
Part of the Pediatric Oncology book series (PEDIATRICO)

Abstract

Significant advances in chemotherapy protocols for the treatment of many childhood cancers have resulted in improved survival rates; however, opportunistic infections continue to plague this vulnerable population, especially with concomitant increased therapeutic intensity. Empiric antibiotic and antifungal therapy in patients with suspected infection have helped limit the effect of such infections although infection persists as a leading cause of treatment-related mortality. Preventative interventions represent an opportunity to reduce the incidence of infection and thus reduce mortality. The pediatric evidence for specific preventative measures to reduce bacterial, fungal and viral infections is reviewed. Areas for future research to improve knowledge regarding infection prevention in children with malignancy are also identified.

Keywords

Acute Lymphoblastic Leukemia Hematopoietic Stem Cell Transplant National Comprehensive Cancer Network Acute Myelogenous Leukemia Invasive Fungal Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. Abshire TC, Pollock BH, Billett AL et al (2000) Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Blood 96:1709–1715PubMedGoogle Scholar
  2. Advisory Committee on Immunization Practices (2012) Recommended adult immunization schedule: United States. Ann Intern Med 156:211–217Google Scholar
  3. Afzal S, Ethier MC, Dupuis LL et al (2009) Risk factors for infection-related outcomes during induction therapy for childhood acute lymphoblastic leukemia. Pediatr Infect Dis J 28:1064–1068PubMedGoogle Scholar
  4. Agrawal A, Chang P, Feusner J (2011) Twice weekly Pneumocystis jiroveci pneumonia prophylaxis with trimethoprim-sulfamethoxazole in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 33:e1–e4PubMedGoogle Scholar
  5. Anderson H, Scarffe JH, Sutton RN et al (1984) Oral acyclovir prophylaxis against herpes simplex virus in non-Hodgkin lymphoma and acute lymphoblastic leukaemia patients receiving remission induction chemotherapy. A randomised double blind, placebo controlled trial. Br J Cancer 50:45–49PubMedCentralPubMedGoogle Scholar
  6. Annaloro C, Della Volpe A, Usardi P et al (2006) Caspofungin treatment of Pneumocystis pneumonia during conditioning for bone marrow transplantation. Eur J Clin Microbiol Infect Dis 25:52–54PubMedGoogle Scholar
  7. Ashley ES, Lewis R, Lewis JS et al (2006) Pharmacology of systemic antifungal agents. Clin Infect Dis 43:28–39Google Scholar
  8. Azuma E, Nagai M, Qi J et al (1998) CD4+ T-lymphocytopenia in long-term survivors following intensive chemotherapy in childhood cancers. Med Pediatr Oncol 30:40–45PubMedGoogle Scholar
  9. Beltz K, Kramm C, Laws H et al (2006) Combined trimethoprim and caspofungin treatment for severe Pneumocystis jiroveci pneumonia in a five year old boy with acute lymphoblastic leukemia. Klin Padiatr 218:177–179PubMedGoogle Scholar
  10. Bleasdale SC, Trick WE, Gonzalez IM et al (2007) Effectiveness of chlorhexidine bathing to reduce catheter-associated bloodstream infections in medical intensive care unit patients. Arch Intern Med 167:2073–2079PubMedGoogle Scholar
  11. Bochud P-Y, Chien JW, Marr KA et al (2008) Toll-like receptor 4 polymorphisms and aspergillosis in stem-cell transplantation. N Engl J Med 359:1766–1777PubMedCentralPubMedGoogle Scholar
  12. Boeckh M, Gooley TA, Myerson D et al (1996) Cytomegalovirus pp 65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study. Blood 88:4063–4071PubMedGoogle Scholar
  13. Boeckh M, Kim HW, Flowers ME et al (2006) Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation—a randomized double-blind placebo-controlled study. Blood 107:1800–1805PubMedCentralPubMedGoogle Scholar
  14. Bolyard EA, Tablan OC, Williams WW et al (1998) Guideline for infection control in healthcare personnel, 1998. Hospital Infection Control Practices Advisory Committee. Infect Control Hosp Epidemiol 19:407–463PubMedGoogle Scholar
  15. Bowden RA, Slichter SJ, Sayers M et al (1995) A comparison of filtered leukocyte-reduced and cytomegalovirus (CMV) seronegative blood products for the prevention of transfusion-associated CMV infection after marrow transplant. Blood 86:3598–3603PubMedGoogle Scholar
  16. Boyce JM, Pittet D (2002) Guideline for hand hygiene in health-care settings. Recommendations of the Healthcare Infection Control Practices Advisory Committee and the HICPAC/SHEA/APIC/IDSA Hand Hygiene Task Force. Soceity for Healthcare Epidemiology of America/Association for Professionals in Infection Control/Infectious Disease Society of America. MMWR Recomm Rep 51:1–45PubMedGoogle Scholar
  17. Bradley JS, Arguedas A, Blumer JL et al (2007) Comparative study of levofloxacin in the treatment of children with community-acquired pneumonia. Pediatr Infect Dis J 26:868–878PubMedGoogle Scholar
  18. Bucaneve G, Micozzi A, Menichetti F et al (2005) Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med 353:977–987PubMedGoogle Scholar
  19. Bueno J, Ramil C, Green M (2002) Current management strategies for the prevention and treatment of cytomegalovirus infection in pediatric transplant recipients. Paediatr Drugs 4:279–290PubMedGoogle Scholar
  20. Burgos A, Zaoutis TE, Dvorak CC et al (2008) Pediatric invasive aspergillosis: a multicenter retrospective analysis of contemporary cases. Pediatrics 121:e1286–e1294PubMedGoogle Scholar
  21. Castagnola E, Boni L, Giacchino M et al (2003) A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer. Pediatr Infect Dis J 22:359–365PubMedGoogle Scholar
  22. Centers for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation (2000) Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 49(1–125):CE1–CE7Google Scholar
  23. Cheng FW, Leung TF, Chan PK et al (2010) Recovery of humoral and cellular immunities to vaccine-preventable infectious diseases in pediatric oncology patients. Pediatr Hematol Oncol 27:195–204PubMedGoogle Scholar
  24. Cherry JD (2012) Epidemic pertussis in 2012–the resurgence of a vaccine-preventable disease. N Engl J Med 367:785–787PubMedGoogle Scholar
  25. Chou L, Lewis R, Ippoliti C et al (2007) Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 27:1644–1650PubMedGoogle Scholar
  26. Chusid MJ, Heyrman KA (1978) An outbreak of Pneumocystis carinii pneumonia at a pediatric hospital. Pediatrics 62:1031–1035PubMedGoogle Scholar
  27. Climo MW, Sepkowitz KA, Zuccotti G et al (2009) The effect of daily bathing with chlorhexidine on the acquisition of methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and healthcare-associated bloodstream infections: results of a quasi-experimental multicenter trial. Crit Care Med 37:1858–1865PubMedGoogle Scholar
  28. Cornely OA, Maertens J, Winston DJ et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356:348–359PubMedGoogle Scholar
  29. Creutzig U, Zimmermann M, Reinhardt D et al (2004) Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 22:4384–4393PubMedGoogle Scholar
  30. Cronin S, Chandrasekar P (2010) Safety of triazole antifungal drugs in patients with cancer. J Antimicrob Chemother 65:410–416PubMedGoogle Scholar
  31. Cullen M, Steven N, Billingham L et al (2005) Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas. N Engl J Med 353:988–998PubMedGoogle Scholar
  32. Cunha C, Di Ianni M, Bozza S et al (2010) Dectin-1 Y238X polymorphism associates with susceptibility to invasive aspergillosis in hematopoietic transplantation through impairment of both recipient- and donor-dependent mechanisms of antifungal immunity. Blood 116:5394–5402PubMedGoogle Scholar
  33. De Pauw B, Walsh T, Donnelly J et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46:1813–1821PubMedCentralPubMedGoogle Scholar
  34. Dvorak CC, Fisher BT, Sung L et al (2012) Antifungal prophylaxis in pediatric hematology/oncology: new choices and new data. Pediatr Blood Cancer 59:21–26Google Scholar
  35. Etminan M, Forooghian F, Brophy JM et al (2012) Oral fluoroquinolones and the risk of retinal detachment. JAMA 307:1414–1419PubMedGoogle Scholar
  36. Feemster KA, Prasad P, Smith MJ et al (2011) Employee designation and health care worker support of an influenza vaccine mandate at a large pediatric tertiary care hospital. Vaccine 29:1762–1769PubMedGoogle Scholar
  37. Fiore AE, Fry A, Shay D et al (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60:1–24PubMedGoogle Scholar
  38. Freifeld A, Bow E, Sepkowitz K et al (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52:427–431PubMedGoogle Scholar
  39. Friberg L, Ravva P, Karlsson M et al (2012) Integrated population pharmacokinetics of voriconazole in children, adolescents, and adults. Antimicrob Agents Chemother 56:3032–3042PubMedCentralPubMedGoogle Scholar
  40. Gafter-Gvili A, Fraser A, Paul M et al (2012) Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 1, CD004386PubMedCentralPubMedGoogle Scholar
  41. Goodman J, Winston D, Greenfield R et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851PubMedGoogle Scholar
  42. Goodrich JM, Bowden RA, Fisher L et al (1993) Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 118:173–178PubMedGoogle Scholar
  43. Granell M, Urbano-Ispizua A, Suarez B et al (2006) Mannan-binding lectin pathway deficiencies and invasive fungal infections following allogeneic stem cell transplantation. Exp Hematol 34:1435–1441PubMedGoogle Scholar
  44. Groll A, Kurz M, Schneider W et al (1999) Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses 42:431–442PubMedGoogle Scholar
  45. Groll AH, Castagnola E, Cesaro S et al (2014) Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 15:e327–e340Google Scholar
  46. Guyatt G, Gutterman D, Baumann MH et al (2006) Grading strength of recommendations and quality of evidence in clinical guidelines: report from an American College of Chest Physicians Task Force. Chest 129:174–181PubMedGoogle Scholar
  47. Hampel B, Hullmann R, Schmidt H (1997) Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use–safety report. Pediatr Infect Dis J 16:127–129; discussion 60–62PubMedGoogle Scholar
  48. Harris R, McCallister J, Allen S et al (1980) Prevention of pneumocystis pneumonia. Use of continuous sulfamethoxazole-trimethroprim therapy. Am J Dis Child 134:35–38PubMedGoogle Scholar
  49. Hayden FG, Gubareva LV, Monto AS et al (2000) Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group. N Engl J Med 343:1282–1289PubMedGoogle Scholar
  50. Helms CM, Polgreen PM (2008) Should influenza immunisation be mandatory for healthcare workers? Yes. BMJ 337:a2142PubMedGoogle Scholar
  51. Henrickson KJ, Hoover SM, Kuhn SM et al (2000) Prevention of central venous catheter–related infections and thrombotic events in immunocompromised children by the use of vancomycin/ciprofloxacin/heparin flush solution: a randomized, multicenter, double-blind trial. J Clin Oncol 18:1269–1278PubMedGoogle Scholar
  52. Hersh EM, Bodey GP, Nies BA et al (1965) Causes of death in acute leukemia: a ten-year study of 414 patients from 1954–1963. JAMA 193:105–109PubMedGoogle Scholar
  53. Hughes WT (1971) Fatal infections in childhood leukemia. Am J Dis Child 122:283–287PubMedGoogle Scholar
  54. Isaacs D, Leask J (2008) Should influenza immunisation be mandatory for healthcare workers? No. BMJ 337:a2140PubMedGoogle Scholar
  55. Jick S (1997) Ciprofloxacin safety in a pediatric population. Pediatr Infect Dis J 16:130–133; discussion 3–4, 60–62PubMedGoogle Scholar
  56. Karlsson M, Lutsar I, Milligan P (2009) Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother 53:935–944PubMedCentralPubMedGoogle Scholar
  57. Kelsey S, Goldman J, McCann S et al (1999) Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study. Bone Marrow Transplant 23:163–168PubMedGoogle Scholar
  58. Kern WV, Klose K, Jellen-Ritter AS et al (2005) Fluoroquinolone resistance of Escherichia coli at a cancer center: epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 24:111–118PubMedGoogle Scholar
  59. Kesh S, Mensah N, Peterlongo P et al (2005) TLR1 and TLR6 polymorphisms are associated with susceptibility to invasive aspergillosis after allogeneic stem cell transplantation. Ann N Y Acad Sci 1062:95–103PubMedGoogle Scholar
  60. Kim J, Smathers SA, Prasad P et al (2008a) Epidemiological features of Clostridium difficile-associated disease among inpatients at children’s hospitals in the United States, 2001–2006. Pediatrics 122:1266–1270PubMedGoogle Scholar
  61. Kim S, Dabb A, Glenn D et al (2008b) Intravenous pentamidine is effective as second line Pneumocystis pneumonia prophylaxis in pediatric oncology patients. Pediatr Blood Cancer 50:779–783PubMedCentralPubMedGoogle Scholar
  62. Klein NP, Bartlett J, Rowhani-Rahbar A et al (2012) Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 367:1012–1019PubMedGoogle Scholar
  63. Kurt B, Flynn P, Shenep JL et al (2008) Prophylactic antibiotics reduce morbidity due to septicemia during intensive treatment for pediatric acute myeloid leukemia. Cancer 113:376–382PubMedGoogle Scholar
  64. Lamaris GA, Ben-Ami R, Lewis RE et al (2009) Increased virulence of zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. J Infect Dis 199:1399–1406PubMedGoogle Scholar
  65. Landry DL, Gobielle SL, Haessler SD et al (2010) Emergence of gentamicin-resistant bacteremia in hemodialysis patients receiving gentamicin lock catheter prophylaxis. Clin J Am Soc Nephrol 5:1799–1804PubMedCentralPubMedGoogle Scholar
  66. LaVela S, Goldstein B, Smith B et al (2007) Working with symptoms of a respiratory infection: staff who care for high-risk individuals. Am J Infect Control 35:448–454PubMedGoogle Scholar
  67. Lawson SE, Harrison G, Richards S et al (2000) The UK experience in treating relapsed childhood acute lymphoblastic leukaemia: a report on the medical research council UKALLR1 study. Br J Haematol 108:531–543PubMedGoogle Scholar
  68. Leahey AM, Bunin NJ, Belasco JB et al (2000) Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia. Med Pediatr Oncol 34:313–318PubMedGoogle Scholar
  69. Lehrnbecher T, Foster C, Vázquez N et al (1997) Therapy-induced alterations in host defense in children receiving therapy for cancer. J Pediatr Hematol Oncol 19:399–417PubMedGoogle Scholar
  70. Lehrnbecher T, Ethier MC, Zaoutis T et al (2009) International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia. Br J Haematol 147:125–128PubMedGoogle Scholar
  71. Levinsen M, Shabaneh D, Bohnstedt C et al (2012) Pneumocystis jiroveci pneumonia prophylaxis during maintenance therapy influences methotrexate/6-mercaptopurine dosing but not event-free survival for childhood acute lymphoblastic leukemia. Eur J Haematol 88:78–86PubMedGoogle Scholar
  72. Licciardello M, Pegoraro A, Cesaro S (2011) Prophylaxis and therapy of viral infections in pediatric patients treated for malignancy. Pediatr Rep 3:e5PubMedCentralPubMedGoogle Scholar
  73. Locatelli F, Testi AM, Bernardo ME et al (2009) Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 147:371–378PubMedGoogle Scholar
  74. Mackall CL, Fleisher TA, Brown MR et al (1995) Age, thymopoiesis, and CD4+ Tlymphocyte regeneration after intensive chemotherapy. N Engl J Med 332:143–149PubMedGoogle Scholar
  75. Maertens J, Madero L, Reilly A et al (2010) A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin B for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J 29:415–420PubMedGoogle Scholar
  76. Maertens J, Marchetti O, Herbrecht R et al (2011) European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3–2009 update. Bone Marrow Transplant 46:709–718PubMedGoogle Scholar
  77. Majetschak M, Flohe S, Obertacke U et al (1999) Relation of a TNF gene polymorphism to severe sepsis in trauma patients. Ann Surg 230:207–214PubMedCentralPubMedGoogle Scholar
  78. Malani P, Bradley S, Little R et al (2001) Trends in species causing fungaemia in a tertiary care medical centre over 12 years. Mycoses 44:446–449PubMedGoogle Scholar
  79. Marr KA, Crippa F, Leisenring W et al (2004) Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 103:1527–1533PubMedGoogle Scholar
  80. Mattiuzzi G, Estey E, Raad I et al (2003) Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer 97:450–456PubMedGoogle Scholar
  81. Mattiuzzi G, Alvarado G, Giles F et al (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50:143–147PubMedCentralPubMedGoogle Scholar
  82. Mazur B, Szczepański T, Karpe J et al (2006) Decreased numbers of CD4+ T lymphocytes in peripheral blood after treatment of childhood acute lymphoblastic leukemia. Leuk Res 30:33–36PubMedGoogle Scholar
  83. Mezger M, Steffens M, Beyer M et al (2008) Polymorphisms in the chemokine (C-X-C motif) ligand 10 are associated with invasive aspergillosis after allogeneic stem-cell transplantation and influence CXCL10 expression in monocyte-derived dendritic cells. Blood 111:534–536PubMedGoogle Scholar
  84. Mora-Duarte J, Betts R, Rotstein C et al (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347:2020–2029PubMedGoogle Scholar
  85. National Comprehensive Cancer Network (2008) Practice guidelines in oncology. Prevention and treatment of cancer related infections. www.nccn.org
  86. Neely M, Rushing T, Kovacs A et al (2010) Voriconazole pharmacokinetics and pharmacodynamics in children. Clin Infect Dis 50:27–36PubMedCentralPubMedGoogle Scholar
  87. Noel GJ, Bradley JS, Kauffman RE et al (2007) Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders. Pediatr Infect Dis J 26:879–891PubMedGoogle Scholar
  88. Noel GJ, Blumer JL, Pichichero ME et al (2008) A randomized comparative study of levofloxacin versus amoxicillin/clavulanate for treatment of infants and young children with recurrent or persistent acute otitis media. Pediatr Infect Dis J 27:483–489PubMedGoogle Scholar
  89. O’Grady NP, Alexander M, Burns LA et al (2011) Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 52:e162–e193PubMedCentralPubMedGoogle Scholar
  90. Oliveira C, Nasr A, Brindle M et al (2012) Ethanol locks to prevent catheter-related bloodstream infections in parenteral nutrition: a meta-analysis. Pediatrics 129:318–329PubMedGoogle Scholar
  91. Owens RC Jr, Ambrose PG (2005) Antimicrobial safety: focus on fluoroquinolones. Clin Infect Dis 41:S144–S157PubMedGoogle Scholar
  92. Pascual A, Calandra T, Bolay S et al (2008) Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 46:201–211PubMedGoogle Scholar
  93. Penack O, Schwartz S, Martus P et al (2006) Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial. Ann Oncol 17:1306–1312PubMedGoogle Scholar
  94. Pfaller M, Castanheira M, Lockhart S et al (2012) Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. J Clin Microbiol 50:1199–1203PubMedCentralPubMedGoogle Scholar
  95. Pizzo PA, Robichaud KJ, Gill FA et al (1979) Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. Am J Med 67:194–200PubMedGoogle Scholar
  96. Pizzo PA, Robichaud KJ, Gill FA et al (1982) Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med 72:101–111PubMedGoogle Scholar
  97. Pizzo PA, Robichaud KJ, Edwards BK et al (1983) Oral antibiotic prophylaxis in patients with cancer: a double-blind randomized placebo-controlled trial. J Pediatr 102:125–133PubMedGoogle Scholar
  98. Popovich KJ, Hota B, Hayes R et al (2009) Effectiveness of routine patient cleansing with chlorhexidine gluconate for infection prevention in the medical intensive care unit. Infect Control Hosp Epidemiol 30:959–963PubMedGoogle Scholar
  99. Prabhu RM, Piper KE, Litzow MR et al (2005) Emergence of quinolone resistance among viridans group streptococci isolated from the oropharynx of neutropenic peripheral blood stem cell transplant patients receiving quinolone antimicrobial prophylaxis. Eur J Clin Microbiol Infect Dis 24:832–838PubMedGoogle Scholar
  100. Rabin KR, Smith J, Kozinetz CA (2012) Myelosuppression and infectious complications in children with Down syndrome and acute lymphoblastic leukemia. Pediatr Blood Cancer 58:633–635PubMedCentralPubMedGoogle Scholar
  101. Raetz EA, Borowitz MJ, Devidas M et al (2008) Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children’s Oncology Group Study[corrected]. J Clin Oncol 26:3971–3978PubMedCentralPubMedGoogle Scholar
  102. Razonable RR, Litzow MR, Khaliq Y et al (2002) Bacteremia due to viridans group Streptococci with diminished susceptibility to Levofloxacin among neutropenic patients receiving levofloxacin prophylaxis. Clin Infect Dis 34:1469–1474PubMedGoogle Scholar
  103. Reboli A, Rotstein C, Pappas P et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356:2472–2482PubMedGoogle Scholar
  104. Redmond AO (1997) Risk-benefit experience of ciprofloxacin use in pediatric patients in the United Kingdom. Pediatr Infect Dis J 16:147–149; discussion 60–62PubMedGoogle Scholar
  105. Riley LC, Hann IM, Wheatley K et al (1999) Treatment-related deaths during induction and first remission of acute myeloid leukaemia in children treated on the Tenth Medical Research Council acute myeloid leukaemia trial (MRC AML10). The MCR Childhood Leukaemia Working Party. Br J Haematol 106:436–444PubMedGoogle Scholar
  106. Robenshtok E, Gafter-Gvili A, Goldberg E et al (2007) Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25:5471–5489PubMedGoogle Scholar
  107. Roman E, Osunkwo I, Militano O et al (2008) Liposomal amphotericin B prophylaxis of invasive mold infections in children post allogeneic stem cell transplantation. Pediatr Blood Cancer 50:325–330PubMedGoogle Scholar
  108. Rosen G, Nielsen K, Glenn S et al (2005) Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 27:135–140PubMedGoogle Scholar
  109. Safdar N, Maki DG (2006) Use of vancomycin-containing lock or flush solutions for prevention of bloodstream infection associated with central venous access devices: a meta-analysis of prospective, randomized trials. Clin Infect Dis 43:474–484PubMedGoogle Scholar
  110. Sangiolo D, Storer B, Nash R et al (2005) Toxicity and efficacy of daily dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic stem cell transplantation: a case–control study. Biol Blood Marrow Transplant 11:521–529PubMedGoogle Scholar
  111. Saral R, Burns WH, Laskin OL et al (1981) Acyclovir prophylaxis of herpes-simplex-virus infections. N Engl J Med 305:63–67PubMedGoogle Scholar
  112. Saral R, Ambinder RF, Burns WH et al (1983) Acyclovir prophylaxis against herpes simplex virus infection in patients with leukemia. A randomized, double-blind, placebo-controlled study. Ann Intern Med 99:773–776PubMedGoogle Scholar
  113. Schaad UB (2007) Will fluoroquinolones ever be recommended for common infections in children? Pediatr Infect Dis J 26:865–867PubMedGoogle Scholar
  114. Schimpff S, Satterlee W, Young VM et al (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284:1061–1065PubMedGoogle Scholar
  115. Schimpff SC, Young VM, Greene WH et al (1972) Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 77:707–714PubMedGoogle Scholar
  116. Science M, Robinson PD, MacDonald T et al (2014) Guideline for primary antifungal prophylaxis for pediatric patients with cancer or hematopoietic stem cell transplant recipients. Pediatr Blood Cancer 61:393–400PubMedGoogle Scholar
  117. Seo K, Kim D, Sohn S et al (2005) Protective role of interleukin-10 promoter gene polymorphism in the pathogenesis of invasive pulmonary aspergillosis after allogeneic stem cell transplantation. Bone Marrow Transplant 36:1089–1095PubMedGoogle Scholar
  118. Shima H, Miharu M, Osumi T et al (2010) Differences in voriconazole trough plasma concentrations per oral dosages between children younger and older than 3 years of age. Pediatr Blood Cancer 54:1050–1052PubMedGoogle Scholar
  119. Siegel JD, Rhinehart E, Jackson M et al (2007) 2007 guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 35:S65–S164PubMedGoogle Scholar
  120. Siegel JH, Korniewicz DM (2007) Keeping patients safe: an interventional hand hygiene study at an oncology center. Clin J Oncol Nurs 11:643–646PubMedGoogle Scholar
  121. Slavin M, Osborne B, Adams R et al (1995) Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation–a prospective, randomized, double-blind study. J Infect Dis 171:1545–1552PubMedGoogle Scholar
  122. Smith J, Safdar N, Knasinski V et al (2006) Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 50:1570–1572PubMedCentralPubMedGoogle Scholar
  123. Steinbach W, Addison R, McLaughlin L et al (2007) Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 26:558–564PubMedGoogle Scholar
  124. Styczynski J, Reusser P, Einsele H et al (2009) Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43:757–770PubMedGoogle Scholar
  125. Sullivan KM, Dykewicz CA, Longworth DL et al (2001) Preventing opportunistic infections after hematopoietic stem cell transplantation: the Centers for Disease Control and Prevention, Infectious Diseases Society of America, and American Society for Blood and Marrow Transplantation Practice Guidelines and beyond. Hematology Am Soc Hematol Educ Program 392–421Google Scholar
  126. Sung L, Lange BJ, Gerbing RB et al (2007) Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood 110:3532–3539PubMedGoogle Scholar
  127. Sung L, Gamis A, Alonzo TA et al (2009) Infections and association with different intensity of chemotherapy in children with acute myeloid leukemia. Cancer 115:1100–1108PubMedCentralPubMedGoogle Scholar
  128. Sung L, Aplenc R, Alonzo TA et al (2013) Effectiveness of supportive care measures to reduce infections in pediatric AML: a report from the Children’s Oncology Group. Blood 121:3573–3577PubMedCentralPubMedGoogle Scholar
  129. Tancrede CH, Andremont AO (1985) Bacterial translocation and gram-negative bacteremia in patients with hematological malignancies. J Infect Dis 152:99–103PubMedGoogle Scholar
  130. Thiele T, Kruger W, Zimmermann K et al (2011) Transmission of cytomegalovirus (CMV) infection by leukoreduced blood products not tested for CMV antibodies: a single-center prospective study in high-risk patients undergoing allogeneic hematopoietic stem cell transplantation (CME). Transfusion 51:2620–2626PubMedGoogle Scholar
  131. Thomson B, Park JR, Felgenhauer J et al (2004) Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Pediatr Blood Cancer 43:571–579PubMedGoogle Scholar
  132. Tomblyn M, Chiller T, Einsele H et al (2009a) Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective. Preface. Bone Marrow Transplant 44:453–455PubMedGoogle Scholar
  133. Tomblyn M, Chiller T, Einsele H et al (2009b) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15:1143–1238PubMedCentralPubMedGoogle Scholar
  134. Trifilio S, Singhal S, Williams S et al (2007) Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 40:451–456PubMedGoogle Scholar
  135. van Burik J, Ratanatharathorn V, Stepan D et al (2004) Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 39:1407–1416PubMedGoogle Scholar
  136. van Eys J, Berry DM, Crist W et al (1987) Effect of trimethoprim/sulfamethoxazole prophylaxis on outcome of childhood lymphocytic leukemia. A Pediatric Oncology Group Study. Cancer 59:19–23PubMedGoogle Scholar
  137. Vardakas K, Michalopoulos A, Falagas M (2005) Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials. Br J Haematol 131:22–28PubMedGoogle Scholar
  138. Vasconcelles M, Bernardo M, King C et al (2000) Aerosolized pentamidine as pneumocystis prophylaxis after bone marrow transplantation is inferior to other regimens and is associated with decreased survival and an increased risk of other infections. Biol Blood Marrow Transplant 6:35–43PubMedGoogle Scholar
  139. von Baum H, Sigge A, Bommer M et al (2006) Moxifloxacin prophylaxis in neutropenic patients. J Antimicrob Chemother 58:891–894Google Scholar
  140. Weber DJ, Consoli SA, Sickbert-Bennett E et al (2012) Assessment of a mandatory tetanus, diphtheria, and pertussis vaccination requirement on vaccine uptake over time. Infect Control Hosp Epidemiol 33:81–83PubMedGoogle Scholar
  141. Welliver R, Monto AS, Carewicz O et al (2001) Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA 285:748–754PubMedGoogle Scholar
  142. Wingard JR, Dick J, Charache P et al (1986) Antibiotic-resistant bacteria in surveillance stool cultures of patients with prolonged neutropenia. Antimicrob Agents Chemother 30:435–439PubMedCentralPubMedGoogle Scholar
  143. Wingard JR, Carter SL, Walsh TJ et al (2010) Randomized double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection (IFI) after allogeneic hematopoietic cell transplantation. Blood 116:5111–5118PubMedCentralPubMedGoogle Scholar
  144. Winston D, Ho W, Bartoni K et al (1993) Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Results of a placebo-controlled, double-blind trial. Ann Intern Med 118:179–184PubMedGoogle Scholar
  145. Wolf J, Shenep JL, Clifford V et al (2013) Ethanol lock therapy in pediatric hematology and oncology. Pediatr Blood Cancer 60:18–25PubMedGoogle Scholar
  146. Wolff S, Fay J, Stevens D et al (2000) Fluconazole vs low-dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American Marrow Transplant Group. Bone Marrow Transplant 25:853–859PubMedGoogle Scholar
  147. Woods WG, Kobrinsky N, Buckley JD et al (1996) Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: a report from the Children’s Cancer Group. Blood 87:4979–4989PubMedGoogle Scholar
  148. World Health Organization (2009) WHO guidelines on hand hygiene in health care. World Health Organization, GenevaGoogle Scholar
  149. Yousef AA, Fryer CJ, Chedid FD et al (2004) A pilot study of prophylactic ciprofloxacin during delayed intensification in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 43:637–643PubMedGoogle Scholar
  150. Zaas A, Liao G, Chien J et al (2008) Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 4:e1000101PubMedCentralPubMedGoogle Scholar
  151. Zaoutis TE, Heydon K, Chu JH et al (2006) Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 117:e711–e716PubMedGoogle Scholar
  152. Ziemann M, Krueger S, Maier AB et al (2007) High prevalence of cytomegalovirus DNA in plasma samples of blood donors in connection with seroconversion. Transfusion 47:1972–1983PubMedGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2015

Authors and Affiliations

  • Brian T. Fisher
    • 1
    Email author
  • Christopher C. Dvorak
    • 2
  • Sarah Alexander
    • 3
  1. 1.Pediatrics, Division of Infectious DiseasesChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  2. 2.Pediatric Stem Cell TransplantationBenioff Children’s Hospital, University of California-San FranciscoSan FranciscoUSA
  3. 3.Pediatric Hematology/OncologyHospital for Sick ChildrenTorontoCanada

Personalised recommendations